ROCKVILLE, Md.--(BUSINESS WIRE)--Prolias, a biotechnology company using proprietary Bead BlotTM technology to develop ligand-based affinity resins that purify and target proteins and protein complexes, today announced that it has launched its first family of ProSpectrum LigandsTM. These ligands are focused on cardiovascular disease, with ligands that bind High-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and cardiac Troponin I proteins.
